What is a stock summary page? Click here for an overview.
Current and historical daily PE Ratio for AGEN (
Agenus Inc
) from 2000 to Apr 29 2025. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Agenus stock (AGEN) PE ratio as of Apr 29 2025 is 0.
More Details
Agenus Inc (AGEN) PE Ratio (TTM) Chart
Agenus Inc (AGEN) PE Ratio (TTM) Historical Data
View and export this data going back to 2000. Start your Free Trial
Total 1215
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Agenus PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2025-04-29 | At Loss | 2025-02-24 | At Loss |
| 2025-04-28 | At Loss | 2025-02-21 | At Loss |
| 2025-04-25 | At Loss | 2025-02-20 | At Loss |
| 2025-04-24 | At Loss | 2025-02-19 | At Loss |
| 2025-04-23 | At Loss | 2025-02-18 | At Loss |
| 2025-04-22 | At Loss | 2025-02-14 | At Loss |
| 2025-04-21 | At Loss | 2025-02-13 | At Loss |
| 2025-04-17 | At Loss | 2025-02-12 | At Loss |
| 2025-04-16 | At Loss | 2025-02-11 | At Loss |
| 2025-04-15 | At Loss | 2025-02-10 | At Loss |
| 2025-04-14 | At Loss | 2025-02-07 | At Loss |
| 2025-04-11 | At Loss | 2025-02-06 | At Loss |
| 2025-04-10 | At Loss | 2025-02-05 | At Loss |
| 2025-04-09 | At Loss | 2025-02-04 | At Loss |
| 2025-04-08 | At Loss | 2025-02-03 | At Loss |
| 2025-04-07 | At Loss | 2025-01-31 | At Loss |
| 2025-04-04 | At Loss | 2025-01-30 | At Loss |
| 2025-04-03 | At Loss | 2025-01-29 | At Loss |
| 2025-04-02 | At Loss | 2025-01-28 | At Loss |
| 2025-04-01 | At Loss | 2025-01-27 | At Loss |
| 2025-03-31 | At Loss | 2025-01-24 | At Loss |
| 2025-03-28 | At Loss | 2025-01-23 | At Loss |
| 2025-03-27 | At Loss | 2025-01-22 | At Loss |
| 2025-03-26 | At Loss | 2025-01-21 | At Loss |
| 2025-03-25 | At Loss | 2025-01-17 | At Loss |
| 2025-03-24 | At Loss | 2025-01-16 | At Loss |
| 2025-03-21 | At Loss | 2025-01-15 | At Loss |
| 2025-03-20 | At Loss | 2025-01-14 | At Loss |
| 2025-03-19 | At Loss | 2025-01-13 | At Loss |
| 2025-03-18 | At Loss | 2025-01-10 | At Loss |
| 2025-03-17 | At Loss | 2025-01-08 | At Loss |
| 2025-03-14 | At Loss | 2025-01-07 | At Loss |
| 2025-03-13 | At Loss | 2025-01-06 | At Loss |
| 2025-03-12 | At Loss | 2025-01-03 | At Loss |
| 2025-03-11 | At Loss | 2025-01-02 | At Loss |
| 2025-03-10 | At Loss | 2024-12-31 | At Loss |
| 2025-03-07 | At Loss | 2024-12-30 | At Loss |
| 2025-03-06 | At Loss | 2024-12-27 | At Loss |
| 2025-03-05 | At Loss | 2024-12-26 | At Loss |
| 2025-03-04 | At Loss | 2024-12-24 | At Loss |
| 2025-03-03 | At Loss | 2024-12-23 | At Loss |
| 2025-02-28 | At Loss | 2024-12-20 | At Loss |
| 2025-02-27 | At Loss | 2024-12-19 | At Loss |
| 2025-02-26 | At Loss | 2024-12-18 | At Loss |
| 2025-02-25 | At Loss | 2024-12-17 | At Loss |
Agenus Inc (AGEN) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Agenus Inc
NAICS : 325414
SIC : 2836
ISIN : US00847G7051
Compare
Compare
Traded in other countries / regions
AGEN.USAAJ8.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2000-02-04Description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers